This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Welcome to the 22nd Annual Healthcare Conference. I’m Matt [Nuremberg] with the Healthcare Services Team, and I’d like to introduce IntegraMed. We have with us from the company, CEO Jay Higham.
Thank you very much. Thanks to Oppenheimer for inviting us to this conference. We appreciate being here. I’m going to take a few minutes to walk through this slide deck and try to leave some time at the end for people to ask questions.
IntegraMed is a healthcare services company. We were founded in 1985, so we’re very well established in the United States. We operate in two highly fragmented segments of healthcare, the fertility services field and the varicose vein treatment.
On a combined basis, these two verticals represent about a $6 billion market in the United States, and IntegraMed is the largest provider in both those two segments. We have very little national competition. Both of them are very competitive in each local market, but from a national level there’s nobody that’s doing quite what we do.
We do have that national footprint, and we have rapid growth really driven three ways, through patient acquisition; through de novo new clinic openings, where we’re launching new clinics in major markets across the country; and also in strategic acquisitions. And we have a strong track record in all three components of the growth. That’s resulted over the last five years in compound average top line growth approaching 14% and EBITDA just over 14%.